Sareum Holdings (LSE:SAR) Construction In Progress : £0.00 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings Construction In Progress?

Sareum Holdings Construction In Progress Historical Data

The historical data trend for Sareum Holdings's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sareum Holdings Construction In Progress Chart

Sareum Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Construction In Progress

Get a 7-Day Free Trial

Sareum Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Sareum Holdings Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Sareum Holdings (LSE:SAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

RYH0:Germany

Address

Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX

Website

http://www.sareum.com

Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.